Dallas, May 23, 2018 — Caddo Medical Technologies, LLC, (“Caddo” or the “Company”) a Dallas based innovator and developer of respiratory care technologies, announces the first closing of its Series A Preferred offering. Proceeds from the offering will be used to further develop the Company’s intellectual property portfolio (the “IP Portfolio”) and to fund its planned outreach to market the IP Portfolio to global leaders in the respiratory care market.
Caddo has invented and patent protected a Pre-filled Nebulizer System (the “PFN™”) the first true drug-device combination applicable to the nebulized medications and devices markets. The drug-device combination calls for pre-filling a sterile, single-use, small volume nebulizer with a precise dose of medication and hermetically sealing the medication in the nebulizer. Caddo has further developed and patent protected a proprietary Breath-enhanced Therapy ‘T’ that marries to and completes the fully assembled nebulizer. Additional pending patents enable the clinician or patient to break the hermetic seal with a quarter turn of the Therapy ‘T’ rendering the sterile device and contents ready for the therapy. After the therapy, the used device is discarded, eliminating the risk of contamination associated with reuse and any need for burdensome, labor-intensive and questionably effective cleaning protocols.
The Caddo Pre-filled Nebulizer System offers a complete and innovative approach to packaging and delivering a broad range of aerosolized medications across numerous nebulizer form factors with each customizable to achieve desired therapy parameters.
The Company’s PFN™ System is patented in 9 major countries including the United States with patents pending in an additional 42 countries.
Mr. Dee Faram, Caddo’s founder and inventor of the PFN™ System, has been in the respiratory care arena for over 35 years. In addition to the PFN™, Mr. Faram invented the Metaneb® System which is a lung therapy device that he licensed to Hill-Rom Holdings, Inc. (NYSE: HRC) in late 2009. Mr. Faram is the named inventor on 30 issued and pending patents spanning 45 governmental jurisdictions. His inventions are primarily in the field of respiratory care.
“The ideation associated with Caddo’s PFN™ grew from years of witnessing firsthand the significant issues associated with legacy nebulizer technology and related treatment protocols — both in hospitals and in-home settings. Across this host of legacy issues, from contamination risks, burdensome cleaning protocols, labor-intensity, misdosing errors and medication spills, our PFN™ effectively addresses them all” commented Mr. Faram.
Faram added, “We see a clear trend in respiratory therapy where the future lies in the joint development of the medication and nebulizer as one system. With the PFN™, we have created a foundational vehicle for pharmaceutical companies and/or device manufacturers to fully capitalize on this drug-device trend. What we have witnessed globally in the adoption and success of the pre-filled syringe is now available, via our PFN™ technology, to provide more convenient, cleaner and safer nebulized treatments for patients with Asthma, COPD, Cystic Fibrosis and other serious lung disorders.”
The Company expects to enter the market in the coming weeks soliciting interest in its IP Portfolio from a carefully selected group of leading companies in the global respiratory care market. Based upon internal analysis, Caddo believes each of these targets could benefit from its PFN™ technology and in-turn stand to maximize the favorable impact of the inventions on patients worldwide.
Caddo Medical Technologies is dedicated to innovation in pulmonary medicine, with a simple mission — to help people breath better. The Company develops and patents creative solutions that align with this mission. Caddo’s advancements in the pulmonary field are guided by its Advisory Board which is comprised of experts and thought-leaders in the global respiratory arena. For more information about the Series A financing, visit sec.info. For more information, visit caddomedical.com
About Respiratory Disease
Asthma is a chronic lung disease that inflames and narrows the airways. Asthma is estimated to affect over 350 million people worldwide. Despite medical advances, more than half of patients continue to experience poor control and significant symptoms impacting their daily lives. The causes of asthma are not completely understood but likely involve an interaction between a person’s genetic make-up and the environment. Key risk factors are inhaled substances that provoke allergic reactions or irritate the airways.
Chronic obstructive pulmonary disease (COPD) is a progressive disease associated mainly with tobacco smoking, air pollution or occupational exposure, which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness. It affects an estimated 320 million people worldwide and is predicted to be the third leading cause of death by 2020. Improving lung function, reducing exacerbations and managing daily symptoms such as breathlessness are important to the management of COPD.
Cystic Fibrosis (CF) is a rare, life-shortening genetic disease affecting approximately 70,000 people worldwide. CF is caused by a defective or missing CFTR protein resulting from mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. There are more than 1,700 known mutations in the CFTR gene. Some of these mutations, which can be determined by a genetic test, or genotyping test, lead to CF by creating non-working or too few CFTR proteins at the cell surface. The defective function or absence of CFTR protein results in poor flow of salt and water into and out of the cell in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death.
Source: Caddo Medical Technologies LLC
Media inquiries and for further information, please contact Evan Faram at 214-919-5377or visit caddomedical.com